Osteoporosis - an immune mediated disease?

Drug Discovery Today: Therapeutic Strategies

Volumn 4, Issue 1, 2007, Pages 3-9

  De Martinis, Massimo ^a   Mengoli, Lucia P ^a   Ginaldi, Lia ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; ESTROGEN; ETANERCEPT; GAMMA INTERFERON; GLYCERYL TRINITRATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IBANDRONIC ACID; IMMUNOGLOBULIN FC FRAGMENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RISEDRONIC ACID; STRONTIUM RANELATE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VITAMIN D;

AGE DISTRIBUTION; AGING; BONE ATROPHY; BONE FRAGILITY; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG TARGETING; ESTROGEN DEFICIENCY; FRAGILITY FRACTURE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; REVIEW; RISK FACTOR;

EID: 37249090724     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2007.09.001     Document Type: Review

References (42)

1. Goldring S.R. Inflammatory mediators as essential elements in bone remodelling. Calcif Tissue 73 (2003) 97-100
2. Yun A.J., and Lee P.Y. Maladaptation of the link between inflammation and bone turnover may be a key determinant of osteoporosis. Med. Hypotheses 63 (2004) 532-537
3. Ginaldi L., et al. Osteoporosis, inflammation and ageing. Immun. Ageing 2 (2005) 1-5
4. De Martinis M., et al. Senile osteoporosis: is it an immune-mediated disease?. Inflamm. Res. 55 (2006) 399-404
5. Haugeber G., et al. Hand cortical bone mass and its associations with radiographic joint damage and fractures in 50-70 year old female patients with rheumatoid arthritis: cross sectional Oslo-Truro-Amsterdam collaborative study. Ann. Rheum. Dis. 63 (2004) 1331-1334
6. Bultink I.E., et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erytematosus. Arthritis Rheum. 52 (2005) 2044-2050
7. Mikuls T.R., et al. Prevalence of osteoporosis and osteopenia among African Americans with early rheumatoid arthritis: the impact of ethinic-specific normative data. J. Natl. Med. Assoc. 97 (2005) 1155-1160
8. Walsh N.C., et al. Bone loss in inflammatory arthritis: mechanisms and treatment strategies. Curr. Opin. Rheumatol. 16 (2004) 419-427
9. Annapoorna N., et al. An increased risk of osteoporosis during acquired immunodeficiency syndrome. Int. J. Med. Sci. 1 (2004) 152-164
10. Leung D.Y., et al. Clinical and immunologic aspects of the hyperimmunoglobulin E syndrome. Hematol. Oncol. Clin. North. Am. 2 (1988) 81-100
11. Moschen A.R., et al. The RANKL/OPG system is activated in inflammatory bwel disease and relates to the state of bone loss. Gut 549 (2005) 479-487
12. Sinigaglia L., et al. Epidemiology of osteoporosis in rheumatic disease. Rheum. Dis. Clin. North Am. 32 (2005) 631-658
13. Abrahamsen B., et al. Utility of testing for monoclonal bands in serum patients with suspected osteoporosis: retrospective, cross sectional study. Br. Med. J. 330 (2005) 818
14. Ishihara K., et al. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 13 (2002) 357-368
15. Koh J.M., et al. Higher circulating hsCRP levels are associated with lower bone mineral density in healthy pre- and post-menopausal women: evidence for a link between systemic inflammation and osteoporosis. Osteopor. Int. 16 (2005) 1263-1271
16. Ganesan K., et al. Relationship of C- reactive protein and bone mineral density in community-dwelling elderly females. J. Natl. Med. Assoc. 97 (2005) 329-333
17. Saidenberg-Kermanac'h N., et al. Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 71 (2004) 9-31
18. Delmas P.D. Treatment of post-menopausal osteoporosis. Lancet 359 (2002) 2018-2026
19. Theill L.E., et al. T cells, bone loss and mammalian evolution. Annu. Rev. Immunol. 20 (2002) 795-823
20. Franceschi C., et al. Inflamm-ageing. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 908 (2000) 244-254
21. Ginaldi L., et al. Chronic antigenico load and apoptosis in immunosenescence. Trends. Immunol. 26 (2005) 79-84
22. Bruunsgard H. Effects of tumor necrosis factor-alpha and interleukin-6 in elderly populations. Eur. Cytokine Netw. 13 (2002) 389-391
23. Nanes M.S.L. Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene 4 (2003) 1-15
24. Effros R.B. Replicative senescence of CD8 T cells: effect on human ageing. Exp. Gerontol. 39 (2004) 517-524
25. Siggelkow H., et al. Cytokines, osteoprotegerin and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J. Bone Miner. Res. 18 (2003) 529-538
26. Wu H., et al. TRAF6, a molecular bridge spanning adaptive immunity, innate immunity and osteoimmunology. Bio Essays 25 (2003) 1096-1105
27. Takayanagi H., et al. Interplay between interferon and other cytokine systems in bone metabolism. Immunol. Rev. 208 (2005) 181-193
28. Khosola S. The OPG/RANKL/RANK system. Endocrinology 142 (2001) 5050-5055
29. Romas E., et al. Involvement of receptor activator of NF Kappa B ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30 (2002) 340-346
30. Yasuda H., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin osteogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Cad. Sci. U. S. A. 95 (1998) 3597-3602
31. Lancey D.L., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
32. Saidenberg Kermanac'h N., et al. Osteoprotegerin and inflammation. Eur. Cytokine Netw. 13 (2002) 144-153
33. Goronzy J.J., et al. The role of T lymphocytes in bone metabolism. Immunol. Rev. 204 (2005) 55-73
34. Weitzmann M.N., et al. The role of T lymphocytes in bone metabolism. Immunol. Rev. 208 (2005) 154-168
35. Weitzmann M.N., and Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 116 (2006) 1186-1194
36. Hartung A.D., et al. Th2-mediated atopic disease protection in Th1-mediated rheumatoid arthritis. Clin. Exp. Rheumatol. 21 (2003) 404-481
37. Ho K.W., et al. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin. Endocrinol. 62 (2005) 92-98
38. Alberti S., et al. Age-dependent modifications of Type 1 and Type 2 cytokines within virgin and memory CD4+ T cells in humans. Mech. Ageing Dev. 127 (2006) 560-566
39. Schwarz E.M., et al. Autoimmunity and bone. Annu. N. Y. Acad. Scl. 1068 (2006) 275-283
40. Raisz L.G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115 (2005) 3318-3325
41. Saidenberg- Kermanac'h N., et al. TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen induced arthritis. Bone 35 (2004) 1200-1207
42. Margolis R.N., and Wimalawansa S.J. Novel targets and therapeutics for bone loss. Ann. N. Y. Acad. Sci. 1068 (2006) 402-409